

June 17, 2009

Affiliation	Investigator Clinical Neuroscience Solutions, Inc. 6867 Southpoint Drive North, Suite 101, Jacksonville, FL 32216
	2008 – Present
Education	7/1990-12/1996 M.B.B.S. (equivalent to M.D.) Seth G.S. Medical College University of Bombay, India
Professional Training	8/2002- 7/2003 Clinical Fellow, Consultation Liaison Psychiatry Department of Psychiatry and Behavioral Sciences Memorial Sloan-Kettering Cancer Center New York, NY
	8/2001-7/2002 Chief Resident 8/2000-7/2001 Resident Division of Child and Adolescent Psychiatry Department of Psychiatry and Behavioral Sciences The Johns Hopkins Medical Institutions Baltimore, MD
	7/1998-7/2000 Resident Department of Psychiatry St. Luke's-Roosevelt Hospital, Columbia University New York, NY
	7/1997-6/1998 Intern Department of Medicine St. Luke's-Roosevelt Hospital, Columbia University New York, NY
Professional Honors	11/2001 Eli Lilly Fellow award at Psychiatric Congress, Boston
License/ Accreditation	Florida- 9/1/2007 # ME 99921 Georgia- 2003 (active) # 053563

June 17, 2009

Experience	2/2007-12/2007	Director, Adolescent Inpatient Unit Focus By The Sea 2927 Demere Rd. St. Simons Island, GA. 31522
	11/2003-2/2007	Child & Adolescent Psychiatrist Satilla Community Services 1003 Mary St., Waycross, GA 31501
Clinical Trial Experience	1999 to Present	<p>Cross Titration of Antipsychotics with XXXX in Schizophrenia and Schizoaffective Disorder – A Multicenter Pilot Study</p> <p>Cost Effectiveness and Functional Outcomes of XXXX in the Treatment of Schizophrenia: A Randomized Clinical Study</p> <p>A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of XXXX with a Lorazepam Arm, in Subjects with Generalized Anxiety Disorder (GAD)</p> <p>A Phase III, Randomized, Double Blind, Multi-Center, Parallel, Group, Placebo Controlled, Forced-dose Titration, Safety and Efficacy Study of XXXX in Adolescents Aged 13-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)</p> <p>A 10 Week, Double-Blind, Placebo Controlled Studies to Evaluate the Efficacy and Safety of XXXX in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down Syndrome, Aged 11 to 17</p> <p>A 52 Week Open-Label safety study of XXXX in subjects with GAD</p> <p>A Randomized, Double-Blind, Parallel Group, Placebo Controlled, Fixed Dose Study Comparing the Efficacy and Safety of 2 Doses of XXXX in Acute Treatment of Adults with Generalized Anxiety Disorder (GAD)</p> <p>A Multicenter, Long Term, Open label Study to Assess the Safety and Tolerability of XXXX as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder (MDD)</p> <p>A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Safety and Efficacy of XXXX as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder (MDD)</p> <p>A Double Blind, Placebo-Controlled Study of XXXX in Bipolar Depression</p> <p>A Double-Blind, Placebo-Controlled study of XXXX as Adjunctive Therapy in</p>

CNS Healthcare of Jacksonville - 6867 Southpoint Drive North, Suite 101, Jacksonville, FL 32216

Tel: (904) 281-5757 - Fax: (904) 281-5758

www.cnshealthcare.com/Jacksonville

June 17, 2009

Major Depressive Disorder (MDD)

A Phase IV, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy study of XXXX in Adults Aged 18-55 with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy of XXXX in Subjects with Major Depressive Disorder

A Double Blind, Efficacy and Safety Study of XXXX versus Place in the Treatment of Children and Adolescents with Major Depressive Disorder (MDD)

A 3-arm, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of XXXX for the Treatment of Adults with Stuttering

A Study of Augmentation with XXXX for Patients with Major Depressive Disorder who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

Randomized, Double Blind, Parallel-Group, Placebo Controlled, Quetiapine-Referenced, Fixed Dose Study of XXXX in the treatment of Depression in Patients with Bipolar I or II Disorder

Randomized, Double Blind, Parallel-Group, Placebo Controlled, Duloxetine-Referenced, Fixed Dose Study Comparing the Efficacy and Safety of XXXX in Acute Treatment of Major Depressive Disorder in Elderly Patients

A Phase IV, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy study of XXX- in adults aged 18-55 with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Double-Blind, Placebo-Controlled study of XXX as adjunctive therapy in Major Depressive Disorder (MDD)

A Double Blind, Placebo-Controlled Study of XXX in Bipolar Depression

A Randomized, Double-Blind, Placebo-and Active Controlled, Parallel Group, Multicenter Study of 3 Dosages of XXX in the Treatment of Adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD)

Certifications

11/2005	American Board of Psychiatry and Neurology- Child & Adolescent
10/2002	American Board of Psychiatry and Neurology- General Psychiatry

June 17, 2009

Professional Organizations	American Academy of Child and Adolescent Psychiatry American Psychiatric Association
Presentations	1/2003 "Psychiatric Aspects of Childhood Cancer" Department of Psychiatry and Behavioral Sciences Memorial Sloan-Kettering Cancer Center
	5/2002 "Behavior Problems in Children and Adolescents: Causes and Treatment Annual Nursing Conference The Johns Hopkins Medical Institutions
	10/2001 Grand Rounds – Case presentation and discussion, Social Phobia and Bulimia Nervosa. Department of Psychiatry and Behavioral Sciences The Johns Hopkins Medical Institutions Baltimore, MD
Reviews, Book Chapters & Miscellaneous Publication	Joshi N , Breitbart W., Psychopharmacologic Management during Cancer treatment. <i>Seminars in Clinical Neuropsychiatry</i> ; 2003
	Villani S., Joshi N : Television and Movies, Rock Music and Music Videos, and Computer and Video Games: Understanding and Preventing Learned violence in the Information Age in <i>Neurobiology of Aggression</i> ; 2003
	Lederberg M, Joshi N : End-of-Life and Palliative Care. <i>Comprehensive Textbook of Psychiatry</i> . Philadelphia: Lippinkott Williams and Wilkins; 2004
	Walkup J, Ritter-Welzant J, Kastelic E, Joshi N , Frosch E: AntidepressantsIII: other agents. <i>Pediatric Psychopharmacology: Principles and Practice</i> ; Andres Martin, M.D., M.P.H. New York, Oxford University Press; 2003